Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Антагонисты рецепторов к ангиотензину II – эволюция представлений
Антагонисты рецепторов к ангиотензину II – эволюция представлений
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Карпов Ю.А. Столетний юбилей открытия ренина. Клинич. фармакол. и тер. 1998; 8: 46–9.
2. Преображенский Д.В., Сидоренко Б.А., Романова Н.Е., Шатунова И.М. Клиническая фармакология основных классов антигипертензивных препаратов. Cons. med. 2002; 2 (3): 99–127.
3. Ferreiro SH. History of the development of inhibitions of angiotensin I conversion. Drugs 1985; 30: 1–5.
4. Kang PM, Landau AJ, Eberhardt RT. Angiotensin II receptor antagonist: A new approaches to blockade of rennin-angiotensin system. Am Heart J 1994; 127: 1388–401.
5. Chung O, Csikys , Linger T. Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertens 1999; 84: 11–20.
6. De Leeuw PW. How do angiotensin II receptors antagonist affect blood pressure? Am J Cardiol 1999; 13 (1): 5–6.
7. Связь между приемом блокаторов рецепторов ангиотензина II и риском развития рака: метаанализ рандомизированных клинических испытаний. Доказательная кардиология. 2010; 3: 17–23.
8. Guidelines for the management of arterial hypertension. Guidelines Committee 2007. European Society of Hypertension/European Society of Cardiology. J Hypertens 2007; 25: 1105–87.
9. Reappraisal of European guidelines on hypertension management: a European Society of Hypertention Task Force document. J Hypertens 2009; 27: 2121–58.
10. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов 2010. www.gypertonic.ru.
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of the 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1665–836.
12. Lindholm LH, Ibsen H, Dahlf B et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359 (9311): 1004–10.
13. Schrader J, Liders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36 (2): 1218–26.
14. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized doubleblind intervention trial. J Hypertens 2003; 21 (5): 875–86.
15. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008; 359 (12): 1225–37.
16. Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
17. Matchar DB, McCrory DC, Orlando LA et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. An Intern Med 2008; 1148: 16–29.
18. Nixon RM, Muller E, Lowy A, Falvey H. Valsartan vs. Other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009; 63 (5): 766–75.
19. Conlin PR, Spence JD, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13 (4 Pt 1): 418–26.
20. Sawada T et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks. KYOTO HEART Study. Eur Heart J 2009; 30 (20): 2461–9.
21. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.
2. Преображенский Д.В., Сидоренко Б.А., Романова Н.Е., Шатунова И.М. Клиническая фармакология основных классов антигипертензивных препаратов. Cons. med. 2002; 2 (3): 99–127.
3. Ferreiro SH. History of the development of inhibitions of angiotensin I conversion. Drugs 1985; 30: 1–5.
4. Kang PM, Landau AJ, Eberhardt RT. Angiotensin II receptor antagonist: A new approaches to blockade of rennin-angiotensin system. Am Heart J 1994; 127: 1388–401.
5. Chung O, Csikys , Linger T. Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertens 1999; 84: 11–20.
6. De Leeuw PW. How do angiotensin II receptors antagonist affect blood pressure? Am J Cardiol 1999; 13 (1): 5–6.
7. Связь между приемом блокаторов рецепторов ангиотензина II и риском развития рака: метаанализ рандомизированных клинических испытаний. Доказательная кардиология. 2010; 3: 17–23.
8. Guidelines for the management of arterial hypertension. Guidelines Committee 2007. European Society of Hypertension/European Society of Cardiology. J Hypertens 2007; 25: 1105–87.
9. Reappraisal of European guidelines on hypertension management: a European Society of Hypertention Task Force document. J Hypertens 2009; 27: 2121–58.
10. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов 2010. www.gypertonic.ru.
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of the 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1665–836.
12. Lindholm LH, Ibsen H, Dahlf B et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359 (9311): 1004–10.
13. Schrader J, Liders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36 (2): 1218–26.
14. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized doubleblind intervention trial. J Hypertens 2003; 21 (5): 875–86.
15. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008; 359 (12): 1225–37.
16. Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
17. Matchar DB, McCrory DC, Orlando LA et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. An Intern Med 2008; 1148: 16–29.
18. Nixon RM, Muller E, Lowy A, Falvey H. Valsartan vs. Other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009; 63 (5): 766–75.
19. Conlin PR, Spence JD, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13 (4 Pt 1): 418–26.
20. Sawada T et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks. KYOTO HEART Study. Eur Heart J 2009; 30 (20): 2461–9.
21. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.
Авторы
Т.В.Адашева, В.С.Задионченко, К.М.Багатырова, Т.М.Терехова
ГОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития РФ
ГОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.